leisure time -WSS

leisure time

author：comprehensive 2025-09-30 19:26:43 - browse：87159

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： AltruBio raises $225 million to develop ulcerative colitis drug

WSS

Warren pushes Witty on UnitedHealth's control over physicians

The creative science of coining drug names

HHS leader on health, climate change and biopharma emissions

Warren pushes Witty on UnitedHealth's control over physicians

How a small hospital in rural Puerto Rico survived Hurricane Maria

AltruBio raises $225 million to develop ulcerative colitis drug

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medical records are filled with copy

Brain MRIs reveal impact of 'toxic stress' on Black children

Malaria cases in Florida and Texas: Here’s what you need to know

Class action alleges UnitedHealth concealed DOJ probe

Virginia high school admissions case could be legal follow

Brain MRIs reveal impact of 'toxic stress' on Black children

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Hospital price transparency does save money, advocate argues

After affirmative action ruling, medical educators look to 'holistic review'

Novel spinal cord stimulator treats paralysis without surgery

hotspot

Is it ever OK for doctors to lie to their patients?

Why health workers in Gaza are injured or die at high rates

Beam Therapeutics to lay off 20% of its staff, re

Will Ozempic

GSK’s asthma push continues as drug succeeds in Phase 3 trials

The creative science of coining drug names

Wikipedia

leisure time

hotspot

explore